Condition: DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: University Medical Center Goettingen
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
This description comes directly from the study's public registry record.
Anna-Carina Hund · +495513961041 · anna-carina.hund@med.uni-goettingen.de
Gerald Wulf · +495513962050 · gerald.wulf@med.uni-goettingen.de
Always discuss trial participation with your own doctor first.
| Universitätsmedizin Göttingen | Göttingen, Lower Saxony, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526065